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Abstract
Background: Type 2 diabetes mellitus (T2DM) incidence is traditionally derived from cohort studies that are not
always feasible, representative, or available. The present study estimates T2DM incidence in Fijian adults from T2DM
prevalence estimates assembled from surveys of 25–64 year old adults conducted over 30 years (n = 14,288).
Methods: T2DM prevalence by five-year age group from five population-based risk factor surveys conducted over
1980–2011 were variously adjusted for urban-rural residency, ethnicity, and sex to previous censuses (1976, 1986, 1996,
2009) to improve representativeness. Prevalence estimates were then used to calculate T2DM incidence based on birth
cohorts from the age-period (Lexis) matrix following the Styblo technique, first used to estimate annual risk of
tuberculosis infection (incidence) from sequential Mantoux population surveys. Poisson regression of year, age,
sex, and ethnicity strata (n = 160) was used to develop projections of T2DM prevalence and incidence to 2020
based on various scenarios of population weight measured by body mass index (BMI) change.
Results: T2DM prevalence and annual incidence increased in Fiji over 1980–2011. Prevalence was higher in Indians
and men than i-Taukei and women. Incidence was higher in Indians and women. From regression analyses, absolute
reductions of 2.6 to 5.1% in T2DM prevalence (13–26% lower), and 0.5–0.9 per 1000 person-years in incidence (8–14%
lower), could be expected in 2020 in adults if mean population weight could be reduced by 1–4 kg, compared to the
current period trend in weight gain.
Conclusions: This is the first application of the Styblo technique to calculate T2DM incidence from population-based
prevalence surveys over time. Reductions in population BMI are predicted to reduce T2DM incidence and prevalence in
Fiji among adults aged 25–64 years.
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Background
As incidence is a measure of new cases of disease occurring
in a given time, it is preferable to using prevalence for ana-
lyzing risk factors and causality, and for projections. Inci-
dence of type 2 diabetes mellitus (T2DM) is normally
derived from cohort studies based on population samples,
such as in Mauritius [1]. However, there may be limitations
of the generalizability of incidence data to the rest of popu-
lation from such cohort studies if they are not representa-
tive; and Hawthorne effects [2] might occur for some risk
factor variables from repeated follow-up of the same
subjects. Incidence of T2DM has also been calculated by
self-report of new doctor-diagnosed T2DM in a defined
retrospective period (such as 12 months) from cross-
sectional surveys [3], as in the 1997 and 2003 United States
National Health Interview Surveys. However, this method
does not include those with undiagnosed hyperglycemia.
New T2DM cases prescribed pharmaceutical treatments
may be measured by notification through prescriptions,
pharmacies, or reimbursement schemes in defined popula-
tions [4–6]. However, such registries may be incomplete
and cannot identify those not prescribed medication for
T2DM. In Denmark, a secular analysis of the national data-
base of people with T2DM receiving medication found that
prevalence increased due to reductions in mortality (in-
creased survival), not due to increases in new registrations
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[6]. Incidence may be back-calculated using compartment
models, as occurs with the WHO DisMod program [7], but
this requires cause-specific mortality data which often are
not complete in low-resource countries.
T2DM incidence from cohort studies in the Pacific
Islands is limited to Samoa [8] and American Samoa [8].
Incidence of T2DM-related morbidity was measured in
Nauru and showed a decline from 26.2 per 1000 person-
years over 1975/76–1982 to 22.5 per 1000 person-years
over 1982–87 [9]. In Samoa, the 4-year T2DM incidence
over 1991–1995 was reported as 1% (29–43 years) and 4%
(44–60 years) in each sex, equivalent to annual incidences
of 2.5 per 1000 person-years (29–43 years) and 10 per 1000
person-years (44–60 years) based on the mean for the four-
year period. When age-adjusted to the 1991 Samoa popula-
tion census [10], this is equivalent to an annual T2DM
incidence of 5.3 per 1,000 person-years for each sex. In
American Samoa for the same age group, the average an-
nual T2DM incidence (age-adjusted to 1990 American
Samoa census) [11] was 28.7 per 1000 person-years (men)
and 21.7 per 1000 person-years (women) over 1990–1994.
In Fiji no prospective cohort study of T2DM has been con-
ducted, but prevalence surveys have been performed over
the last three decades. Analysis of T2DM prevalence trends
based on six population surveys in Fiji indicates an increase
from 7.7 to 15.6% between 1980 and 2011, with projection
to 2020 estimated to be 19.3% [12]. Fiji’s population, ap-
proximately 828,000 at the most recent 2007 census, com-
prises 57% Melanesian (i-Taukei) and 38% Indian. The
remaining 5% is heterogeneous and is composed of Asian,
European, and other Pacific island populations [13].
It is possible to determine disease incidence from con-
secutive prevalence surveys from sequential samples in a
population if the surveys are stratified by age and utilize
similar methodology. This was demonstrated in the 1960s
using recurrent prevalence surveys of tuberculosis infec-
tion, ascertained through Mantoux (tuberculin) skin tests,
to determine the annual (incidence) rate of infection using
birth cohorts from an age-period (Lexis) matrix [14]. No
publications have been located using this technique to cal-
culate (aggregate) incidence rates from prevalence surveys
for T2DM.
In the present study, population-based prevalence surveys
of T2DM and obesity conducted between 1980 and 2011 of
Fijian adults aged 25–64 years are used to calculate T2DM
incidence. T2DM prevalence and incidence are projected
to 2020 using body mass index (BMI) as a predictor vari-
able under different scenarios of population obesity.
Methods
Survey selection
Unit records from five non-communicable disease (NCD)
risk factor population surveys were included for analysis (n
= 14,288): the 1980 National Cardiovascular Disease and
Diabetes Survey (NCVDS) [15], 1993 National Nutrition
Survey (NNS) [16], 2002 Fiji STEPS [17], 2004 NNS [18],
and 2011 Fiji STEPS [Draft WHO STEPS report]. Eight
other cross-sectional health surveys conducted in Fiji since
1952 [19–26] could not be included in this analysis as unit
records were unavailable, and published tabulated data
could not be disaggregated into urban-rural, ethnicity, sex
and five-year age groups. Consequently, these could not be
made nationally representative. Only adults aged 25–64
years who were of i-Taukei (Fiji Melanesian) or Asian In-
dian descent and had a confirmed fasting status for fasting
plasma glucose (FPG) were included. Those of “Other” eth-
nicity (<5%) were excluded due to the heterogeneity of this
group, along with pregnant women where gestational dia-
betes can artifactually inflate the prevalence of T2DM.
T2DM prevalence
In the 1980 NCVDS, glucose was measured in plasma from
venous blood; for the 2011 STEPS, glucose was measured
in capillary whole blood, but reported calibrated to a plasma
concentration. T2DM was defined as FPG ≥7.0 mmol/L
and/or on medication for T2DM [27]. Both the 1993 and
2004 NNS measured T2DM prevalence using self-report.
In order to adjust to T2DM diagnosed including blood
samples, logistic regression models were derived from the
2002 STEPS survey to adjust for under-enumeration of
T2DM from self-report only data. In each sex-specific
model, T2DM (FBG ≥6.1 mmol/L [whole blood glucose]
and/or on medication) was modeled with ethnicity, age,
BMI, and self-reported doctor-diagnosed T2DM status
and/or on T2DM medication (for 2004 NNS), or self-
reported, doctor-diagnosed T2DM status only (for 1993
NNS). Further details on the methods used to adjust self-
reported T2DM data have been published previously [12].
For each survey, the five-year prevalence for each ethnic-
specific sex group, and nationally, was calculated after being
variously case weighted for urban-rural, ethnicity, and sex
to the nearest previous census to minimize selection bias
and improve representativeness at the time of each survey.
Case weights were derived by dividing the proportion of
the census sub-group by the equivalent proportion in the
survey sub-group. Age-specific data were then age-
standardized to the nearest previous census. Confidence
intervals were calculated using binomial methods [28]. Ad-
justed T2DM prevalence counts for each survey year were
then derived by multiplying the adjusted prevalence by the
survey population for each sub-group.
T2DM incidence
Annual T2DM incidence was estimated by adapting the
method developed by Styblo et al. [14] to estimate tuber-
culosis incidence from prevalence of tuberculosis infection
as assessed by sequential surveys of Mantoux positivity.
The method commences with prevalence estimates of a
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disease for a given age and period, and hence year of birth.
The mean annual probability of not acquiring the disease,
from year of birth to a given age, for a given observation
year, is then estimated from this prevalence. For each
given age, a straight line is then fitted through a mathem-
atically convenient transformation of this mean probability
as a function of the year of observation. The regression β-
estimate for this trend is used in conjunction with the
observed prevalence for the given year and age group to
estimate the cumulated probability of not having the con-
dition for that age and year (according to formula (3) in
Additional file 1: Supplement S1). One minus this quantity
becomes the incidence estimate for the given age group
and year. The details of this procedure are provided in
Additional file 1: Supplement S1.
As the intervals between the surveys used for this
study were not evenly spaced, age-specific T2DM preva-
lences were interpolated between the survey years to
produce estimates of annual age-specific prevalences of
T2DM for each sex and ethnic group, and the above
procedure was applied to each interpolated prevalence.
Annual age-specific incidence estimates for each sex
and ethnic group were then directly age-standardized to
the 2007 Fiji census 25–64 year population separately by
sex and ethnicity, and also nationally, to produce five in-
cidence trends for 1980–2011 for ages 25–64 years. Esti-
mated age-specific incidence projected to 2020, based on
T2DM prevalence projected to 2020, was also directly
age-standardized (2007 Census).
Confidence intervals (95%) are based on the normal ap-
proximation to the binomial using the survey populations
for each survey year. For years between surveys, interpo-
lated populations were calculated using the adjacent sur-
veys. Counts of incident cases of T2DM for each survey
year were derived by multiplying the estimated incidence
rates by the survey population for each sub-group. The cu-
mulative incidence risk (%) was calculated as [1-exp(-
x)]*100, where x is the cumulative incidence rate, derived
from the sum of age-specific incidence rates (r) times each
age interval (n); i.e., Ʃ r*n [29].
Projection of T2DM prevalence and incidence based on
obesity scenarios
Projections of T2DM prevalence in Fiji have been calcu-
lated based on period trends [13]. In this analysis, the esti-
mated annual counts of T2DM prevalence and incidence
are modeled by Poisson regression against survey year (n
= 5), ethnicity (n = 2), sex (n = 2), five-year age group (n =
8), and mean BMI for each of the resulting 160 strata.
Mean BMI values for 2020 were derived from a random-
effects linear meta-regression of six surveys [13] and used
in the model to produce T2DM prevalence and incidence
projection estimates for 2020 from models that incorpor-
ate BMI.
BMI-based projections of T2DM prevalence and inci-
dence in 2020 are then re-estimated according to several
population weight change scenarios, expressed as BMI:
(1) mean population weight continues to increase at the
current rate – predicted 2020 mean BMI from a linear
period trend [13]; (2) mean population weight is main-
tained at 2011 levels (i.e., no weight or BMI gain); and
(3) mean population weight is reduced or increased by
1–4 kg (with consequent changes in BMI) compared to
2011 levels, 2011 being the most recent year for which
nationally representative empirical population survey
data are available. A 1–4 kg weight change was selected
as this represents a feasible 0–5% body mass change.
Projected T2DM incidence rates in 2020 based only on
period trends are compared to projected incidence rates
for the same year from Poisson regression models in-
cluding mean BMI for various obesity scenarios.
Data were analysed using SAS 9.4 [SAS Institute Inc.,
Cary, NC, USA], SPSS 22 [IBM Corp., Armonk, NY, USA],
and Microsoft Excel [Microsoft, Redmond, WA, USA].
Results
T2DM prevalence
T2DM prevalence increased with period and age, both
nationally and in all ethnic-specific sex groups (Table 1,
Fig. 1, Additional file 1: Supplement S2). Prevalence is
higher in Indians than i-Taukei (Fiji Melanesian), and
higher in i-Taukei women than i-Taukei men. In Indians,
this is reversed: prevalence in men is higher than in
women. Prevalence was highest in the oldest age groups
and lowest in the youngest age groups.
Projected national T2DM prevalence in 2020 based only
on period trends is 19.3% (Table 2), and the projection
based on period and linear increases in BMI is 20.6%. Na-
tional T2DM prevalence is projected to reach 18.8% in
2020 if mean population weight is maintained at 2011
levels. For a mean population weight reduction of 1–4 kg
Table 1 Diabetes (T2DM) prevalence (%) for Fiji adults aged 25–
64 years in each survey year
1980 NCVDS 1993 NNS 2002 STEPS 2004 NNS 2011 STEPS
25–29 1.8 3.7 5.8 4.6 3.6
30–34 4.9 5.6 5.3 5.9 9.0
35–39 5.5 8.4 9.5 8.5 6.7
40–44 7.2 11.0 15.5 12.3 18.7
45–49 11.3 17.2 20.2 20.0 20.0
50–54 18.3 19.9 31.9 24.3 26.7
55–59 15.5 24.5 36.3 33.0 29.0
60–64 17.0 26.5 36.2 35.6 36.8
25–64a 7.7 11.1 16.5 14.5 15.6
95% CI 7.4–8.0 10.7–11.6 15.9–17.1 14.0–14.9 15.1–16.2
aAge-standardized to nearest previous census
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from 2011 levels, T2DM prevalence is projected as 17.9–
15.5%. On average, for every 1-kg decrease in mean popula-
tion body weight there is a 0.8% reduction in T2DM
prevalence. When mean population weight is increased by
1–4 kg from 2011 levels, projected T2DM prevalence in
2020 is 19.8–23.0%. On average, for every 1-kg increase in
mean population body weight there is a 1.1% increase in
T2DM prevalence.
T2DM incidence
Annual national age-standardized T2DM incidence is es-
timated to have increased from 2.6 to 5.0 per 1000
person-years between 1980 and 2011 (Table 3, Fig. 2,
Additional file 1: Supplement S2). The incidence rate in-
crease has remained similar between the sexes in i-
Taukei. In Indians, incidence is rising faster in women
than in men, and has been higher than in men since
1990. Overall, between ages 25 and 64 years, the esti-
mated cumulative risk of acquiring T2DM increased from
22% in 1980 to 37% in 2010, and by 2020 is projected to
be 42%.
National annual T2DM incidence based on current-
period BMI increases is projected to be 6.4 per 1000
person-years in 2020 (Table 4), higher than projected in-
cidence based on period alone (5.8 per 1000 person-
years). Projected ethnic- and sex-specific incidence rates
in 2020 are also higher using BMI in Poisson regression
models than in models with period alone (Table 4): i-
Taukei men: 5.6 compared to 5.0 per 1000 person-years;
i-Taukei women: 6.8 compared to 5.7 per 1000 person-
years; Indian men: 8.0 compared to 7.2 per 1000 person-
years; Indian women: 9.3 compared to 9.1 per 1000
person-years.
If the population weight is maintained at 2011 levels,
annual national T2DM incidence for 2020 is estimated
as 6.1 per 1000 person-years, equivalent to a reduction
of 0.3 incident cases per 1000 population in 2020 com-
pared to projected incidence in 2020 assuming a con-
tinuation of the current-period BMI trend (6.4 per 1000
person-years). If mean population weight is reduced by
1 kg from 2011 levels, T2DM incidence in 2020 is ex-
pected to be 5.9 per 1000 person-years, equivalent to
preventing 0.5 cases per 1000 in 2020 compared to the
current BMI trend; and a 4-kg reduction in mean weight
results in an estimated T2DM incidence of 5.5 per 1000
person-years in 2020, equivalent to a reduction of 0.9
cases per 1000 in 2020 compared to the current BMI
trend. Conversely, increases of 1, 2, 3, and 4 kg in weight
by 2020 are projected to increase T2DM by 0.2, 0.4, 0.5,
and 0.7 per 1000 person-years by 2020, respectively,
compared to weight maintenance at 2011 levels.
Discussion
This study demonstrates an application to T2DM of a
method for calculating annual incidence from sequential
prevalence surveys. The method is extended to allow
utilization of sequential prevalence surveys conducted
over varying intervals to estimate annual T2DM inci-
dence. Incidence is considerably more relevant than
prevalence in studies of causality, has been used in dis-
ease burden estimation as a component of years lived
with disability [30, 31], and is useful for estimating cases
prevented by interventions.
From estimates of T2DM prevalence for 2020 based on
linear trends [13], prevalence of T2DM in Fiji was pre-
dicted to be 19.3%, an increase from 15.6% in the last em-
pirical survey (2011). By comparison, the IDF Diabetes
Atlas estimate of T2DM prevalence in 2013 (10.9%) [32]
was much lower, likely because they used a single survey
to inform their statistical model [33], which used extensive
forward and backward projections. We used six preva-
lence surveys to inform our modeling, which improves
generalizability and limits use of extensive projection. In
the present study, projections based on the effects of
period, age, and linear trends in BMI, national T2DM
prevalence in Fiji for 2020 is estimated to be 20.6%.
Cohort [34–36] and case-cohort [36] studies have dem-
onstrated a positive association between T2DM incidence
and weight gain. The InterAct study [36] in European
populations found that for every unit standard deviation
(SD) increase in BMI (4 kg/m2), the hazard ratio for
T2DM incidence over 10 years was approximately 2.0,
Fig. 1 Diabetes (T2DM) prevalence (%) in Fiji adults aged 25–64 years,
1980–2011. Black squares= i-Taukei men; black circles= i-Taukei women;
white squares= Indian men; white circles= Indian women. T2DM
prevalence was adjusted for urban-rural and age to nearest previous
census. Trend lines were derived from meta-regression of adjusted survey
prevalences weighted by the inverse of the SE
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Table 2 T2DM prevalence (%) projections to 2020 based on various body mass index (BMI) scenarios, 2011–2020
T2DM prevalence (%) and 95% CI
i-Taukei Indian Fiji
Men Women Men Women



























































































































aAdjusted variously for urban-rural, ethnicity, sex, and age to 2007 census [13]
bFrom linear meta-regression of T2DM prevalence estimates from six surveys, age-adjusted [13]
cFrom ethnic-specific Poisson models using survey year, sex, age, and mean BMI
Table 3 Estimated annual T2DM incidence (per 1,000 person-years) and cumulative risk for Fiji adults aged 25-64 years for each
survey year, 1980–2011
1980 1993 2002 2004 2011
25–29 1.07 1.54 1.86 1.94 2.19
30–34 1.54 2.02 2.35 2.43 2.69
35–39 1.99 2.24 2.41 2.45 2.59
40–44 2.20 3.71 4.81 5.05 5.94
45–49 3.44 4.63 5.50 5.69 6.38
50–54 4.62 5.88 6.80 7.00 7.75
55–59 4.68 6.90 8.57 8.95 10.35
60–64 4.78 6.48 7.74 8.18 9.08
25–64a 2.61 3.58 4.28 4.45 5.02
95% CI 2.52–2.69 3.30–3.86 4.04–4.53 4.19–4.70 4.72–5.31
Cumul risk (%) 25–64 21.60 28.40 32.99 34.09 37.48
95% CI 19.79–23.40 26.30–30.50 31.04–34.94 32.44–35.74 35.46–39.49
Incidence calculated by the Styblo birth cohort method [14]
aAge-standardized to nearest previous censuses
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compared to those who did not gain weight over 10 years
(average for both sexes).
Projections for Fiji imply that prevention of new T2DM
cases can be achieved by reducing population average
weight by relatively small amounts. The impact of such
T2DM disease reduction would likely contribute to im-
provements in premature mortality rates and life expect-
ancy, which have been adversely affected by increases in
NCDs [37, 38]. We estimate that the rate of new cases di-
agnosed each year in Fijian adults in 2020 would decrease
by 0.2–0.6 per 1000 person-years compared to population
weight stabilization at 2011 levels. The reductions are
higher when compared to the expected BMI for 2020
based on the current BMI trend increase (0.5–0.9 per
1000 person-years).
Few examples of sustained countrywide population
weight loss over several years and subsequent reductions in
NCDs have been documented. Most come from observa-
tional studies of countries undergoing significant economic
or social changes such as Cuba [39] following the dissol-
ution of the Soviet Union. After 1991, Cuba lost subsidies
for food and fuel, which resulted in reductions in energy in-
take, changes in food availability (e.g., substituting vegetable
oils for saturated fat), and increased active transport (e.g.,
walking, cycling) in place of automobiles. T2DM incidence
in Cuba from diabetes registries based on primary care was
stable between 1980 and 1989 (1.5–1.8 per 1000 person-
years), but fell over 1990–2000 to 1.2 per 1000 person-
years. Fiscal policies to encourage healthier lifestyles may
be an effective tool in reducing NCD risk factors compared
to health education programs alone. In the Pacific, health
promotion campaigns against obesity have been operating
for many years but obesity still continues to rise [13, 40]. In
Tonga, animal fats and soft drinks are subject to an excise
of Tonga Pa’anga (TOP) $1.00 per kg and TOP$0.50 per
litre, respectively [41]. Such fiscal measures could be repli-
cated in Fiji, but their effects have yet to be established.
The annual T2DM incidence rates in i-Taukei men (2.3
per 1000 person-years) and women (2.8 per 1000 person-
years) over 1990–1994 were lower compared to Samoa
(5.3, each sex) over 1991–1995 [9]; and American Samoa
over 1990–1994 of (28.7, men and 21.7, women) – for
comparable age groups [9]. The lower annual incidence in
Fiji i-Taukei compared to Samoans and American Sa-
moans may be related to lower levels of obesity in Fiji [12]
compared to Samoa and American Samoa. Between 1980
and 2011, obesity prevalence (BMI ≥30 kg/m2) increased
at a rate of 3.0% per five years in i-Taukei men (from 12.6
to 28.9%) and 3.8% per five years in i-Taukei women
(30.1–52.9%) [13]. For a similar period (1978–2013), the
rate of obesity increase in Samoans was 3.6% per five years
in men (from 23.5 to 53.1%), and 4.6% per five years in
women (43.7 to 73.4%) [42], with higher baseline obesity
prevalence in Samoans also indicating a longer duration of
obesity than in Fiji. Both magnitude and duration of obes-
ity have been shown to affect increases in T2DM inci-
dence, which has been demonstrated in Pima Indians [43],
American men and women [34, 35], British men [44], and
Japanese men [45]. Relatively high T2DM incidence rates
have been reported in other small island states such as
Mauritius, where estimated incidence averaged 21.0 per
1000 person-years over 1987–1998 [2].
The method used to estimate T2DM incidence in this
study circumvents numerous pitfalls compared to trad-
itional methods of calculating T2DM incidence, including
cohort studies affected by low generalizability and/or attri-
tion bias, under-enumeration of cases of T2DM not in-
cluded on pharmaceutical registers, or on self-report of
diagnosed T2DM within a reference period from cross-
sectional surveys. To the authors’ knowledge, the present
study is the first to apply Styblo’s birth cohort incidence
calculation method to estimate T2DM incidence. From a
statistical perspective, the main drawback encountered
using the method was underdispersion in subsequent Pois-
son regression modeling of factors associated with T2DM
incidence.
Conclusion
T2DM incidence has increased in all population groups
in Fiji, and the increase is expected to continue into the
near future. This study demonstrates a novel method of
calculating incidence from already available data from
Fig. 2 Estimated T2DM incidence (per 1,000 person-years) in Fiji adults
aged 25–64 years, 1980–2010, with projection to 2020. Black squares= i-
Taukei men; black circles= i-Taukei women; white squares= Indian men;
white circles= Indian women. Solid line = interpolated and modeled
incidence using the Styblo birth cohort method. Broken
line = projected incidence
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previous sequential population-based prevalence sur-
veys, with projections based on various population
weight change scenarios, which may be replicated in
other countries. Estimates and projections of incidence
of T2DM and its accumulated risk over an adult lifetime
provide policymakers with indicators of the expected
burden of new cases of T2DM in Fiji and highlight
population groups most at risk of the disease.
Additional file
Additional file 1: Supplement 1: Method for deriving estimates of
T2DM incidence; and Supplement 2: Age-specific T2DM prevalence by
ethnicity and sex. (DOCX 331 kb)
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aIncidence for 2011 and 2020 is based on applying the Styblo birth cohort method to prevalence estimates, by sex and ethnicity, age-adjusted
bFrom ethnic-specific Poisson models using survey year, sex, age, and mean BMI
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